I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
MIF Antagonist, ISO-1 inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC50 = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. MIF Antagonist, ISO-1 has been shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model.
Stanislava Stosic-Grujicic.; Ivana Stojanovic.; Ferdinando Nicoletti. MIF in autoimmunity and novel therapeutic approaches. Autoimmunity Reviews. 2009, 8, (3), 244-249.
Benjamin W. Fischer-Valuck.; Bonnie L. Barrilleaux.; Donald G. Phinney.; Katie C. Russell.; Darwin J. Prockop.; Kim C. O Connor. Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnology Letters. 2010, 32, (1), 19-27.